Cadila Pharmaceuticals Ltd. launches Esomeprazole tablets under brand name Esiloc™ in India for treatment of hyperacidity.
Ahmedabad-based Cadila pharmaceuticals recently announced the launch of Esomeprazole tablets for treatment of hyperacidity & drug induced gastritis under the brand name Esiloc™. In an endeavor to improve the treatment options available for hyperacidity & drug induced Gastritis, Esiloc™ will be 50% more economical, thus making it a superior yet affordable choice. Esiloc™ will be made available in 20 mg and 40 mg tablets.
Esomeprazole which is a proton pump inhibitor (PPI*), acts on the luminal surface of gastric parietal cells, resulting in inhibition of acid secretion. Esomeprazole provides higher rates of healing of erosive GERD and sustained resolution of heartburn in patients.
Gastro-oesophageal reflux (GERD) is a reflux of gastric contents into the oesophagus. Heart burn is a very common symptom of GERD. GERD is often overseen and if untreated, can lead to conditions like peptic ulcer, chest pain, esophagus cancer & other fatal conditions.
Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies of India. It has recently concluded and cleared USFDA inspection successfully in February 2020. Over the past six decades, Cadila pharmaceuticals has been engaged in development and manufacturing of affordable medicines and in making them available for patients across the world. Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.
Reference:
*Ther Clin Risk Manag. 2007 Aug; 3(4): 653–663. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374928/
